YOLFTbeta
Agenus Inc

Agenus Inc

AGEN · NASDAQ · Healthcare / Biotechnology

6.73USD-0.14 (-2.04%)

Price History

Full chart

Market Stats

Previous Close6.87
Open6.97
Day Range6.50 – 6.97
52-Week Range2.71 – 8.85
Volume464.10K
Market Cap385.68M
P/E (TTM)2.82
Forward P/E3.73
EPS3.03
Dividend Yield0.00%
Beta1.40
50-Day Avg7.27
200-Day Avg4.44

About

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Garo H. Armen Ph.D.
  • Employees81
  • Headquarters3 Forbes Road, Lexington, MA, United States, 02421-7305, USA
  • Websitehttps://www.agenusbio.com

Leadership

  • Dr. Garo H. Armen Ph.D.Founder, Interim CFO, Principal Financial Officer, CEO & Executive Chairman · b. 1953
  • Dr. Steven J. O'Day M.D., Ph.D.Chief Medical Officer · b. 1961
  • Dr. Jennifer S. Buell Ph.D.Director and President & CEO of MiNK Therapeutics · b. 1975
  • Craig WinterChief Information Officer
  • Mr. Zack ArmenVice President of Investor Relations & Corporate Development
  • Ms. Stefanie Perna-NacarChief Communications & Government Relations Officer
  • Ms. Tracy Mazza ClementeChief People Officer
  • Dr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic Advisor
  • Dr. Robin G. Taylor M.B.A., Ph.D.Chief Commercial Officer
  • Dr. Kamel Djazouli M.D.Head of Medical Affairs

Financials

Income Statement

Currency: USD1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue100.00K442.63K4.55M3.41M4.45M707.07K629.98K692.13K5.55M2.65M3.33M3.36M2.76M15.96M3.04M6.98M24.82M22.57M42.88M36.78M150.05M88.17M295.67M98.02M156.31M103.46M114.20M
Growth (%)-+342.63%+929.08%-25.10%+30.43%-84.11%-10.90%+9.87%+702.20%-52.25%+25.76%+0.77%-17.97%+479.18%-80.92%+129.13%+255.70%-9.04%+89.95%-14.21%+307.92%-41.24%+235.34%-66.85%+59.47%-33.81%+10.37%
Cost of Revenue--1.31M1.06M1.34M1.94M4.80K67.36M43.47M33.41M35.82M26.74M122.95K19.59M11.24M13.54M22.35M70.44M94.97M116.13M124.60M168.34M144.97M182.08M197.26M237.68M156.01M80.36M
Gross Profit100.00K1.76M3.49M2.07M2.51M702.27K629.98K692.13K5.55M2.65M3.33M3.24M2.76M4.72M-10.50M-15.37M-45.63M-72.40M-73.25M-87.82M-18.29M-56.80M113.59M-99.23M-81.37M-52.55M33.84M
Gross Margin100.00%396.55%76.64%60.80%56.37%99.32%100.00%100.00%100.00%100.00%100.00%96.34%100.00%29.60%-344.70%-220.32%-183.85%-320.73%-170.83%-238.74%-12.19%-64.42%38.42%-101.24%-52.05%-50.79%29.63%
Operating Expense18.90M28.44M45.12M59.45M70.24M70.39M74.54M51.31M38.83M40.49M31.01M24.99M21.84M11.46M14.48M27.95M35.07M35.08M30.55M36.00M51.85M60.44M87.84M80.19M78.18M67.92M54.39M
Operating Income-18.80M-26.69M-41.63M-57.37M-67.74M-69.69M-73.91M-50.61M-33.28M-37.84M-27.68M-21.75M-19.09M-6.74M-24.98M-43.32M-80.70M-107.48M-103.80M-123.82M-70.14M-117.23M25.75M-179.43M-159.55M-120.47M-20.56M
Operating Margin-18800.00%-6028.85%-913.87%-1681.80%-1522.25%-9855.80%-11732.77%-7312.63%-599.35%-1427.48%-830.19%-647.47%-692.61%-42.23%-820.36%-620.91%-325.18%-476.13%-242.09%-336.62%-46.74%-132.96%8.71%-183.04%-102.07%-116.44%-18.00%
EBITDA-17.86M-25.01M-37.48M-51.91M-60.48M-63.41M-65.55M-42.94M-26.39M-37.84M-20.86M-13.60M-16.81M-5.12M-24.39M-39.64M-84.71M-104.73M-95.82M-130.48M-63.45M-114.63M43.78M-161.85M-145.92M-101.30M62.19M
EBITDA Margin-17857.00%-5650.13%-822.81%-1521.57%-1359.10%-8968.02%-10404.55%-6203.46%-475.29%-1427.49%-625.80%-404.72%-610.13%-32.07%-801.11%-568.16%-341.34%-463.97%-223.47%-354.73%-42.28%-130.01%14.81%-165.11%-93.35%-97.91%54.46%
Net Income-18.10M-46.73M-73.54M-55.88M-65.93M-56.16M-74.10M-51.88M-36.80M-28.70M-30.32M-21.91M-23.28M-11.32M-30.07M-42.49M-87.88M-127.00M-120.69M-159.69M-107.66M-180.91M-23.93M-220.07M-245.76M-227.21M115.00K
Net Income Margin-18100.00%-10557.24%-1614.51%-1637.92%-1481.76%-7942.85%-11762.88%-7495.73%-662.70%-1082.49%-909.36%-652.05%-844.63%-70.95%-987.62%-608.94%-354.12%-562.60%-281.48%-434.14%-71.75%-205.19%-8.09%-224.51%-157.22%-219.61%0.10%
R&D11.00M17.58M31.36M39.98M48.53M41.72M47.08M28.64M21.79M20.66M16.90M12.88M11.02M10.56M13.01M22.35M70.44M94.97M116.13M124.60M168.34M142.62M178.61M16.98M234.57M155.53M79.34M
R&D as % of Total Revenue11000.00%3970.64%688.41%1171.99%1090.57%5900.05%7473.20%4138.43%392.42%779.42%506.99%383.31%399.97%66.19%427.09%320.32%283.85%420.73%270.83%338.74%112.19%161.75%60.41%17.32%150.06%150.32%69.48%
Interest Expense0424.65K690.00K365.17K247.07K530.88K2.96M3.29M4.99M5.08M5.34M4.87M4.21M4.72M2.43M1.26M6.60M17.32M18.87M25.27M41.45M61.08M65.72M61.86M97.92M117.63M55.27M
Interest Expense % of Total Revenue0.00%95.94%15.15%10.70%5.55%75.08%470.41%475.15%89.79%191.62%160.31%145.00%152.77%29.56%79.73%18.08%26.59%76.71%44.01%68.71%27.63%69.27%22.23%63.11%62.65%113.69%48.40%

Balance Sheet

Currency: USD1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets56.00M127.97M93.55M89.06M140.08M133.06M104.15M72.95M44.54M56.95M45.87M30.91M19.81M34.67M34.84M74.53M242.23M156.99M138.40M136.40M155.34M214.51M465.96M413.56M313.91M226.27M226.80M
Total Liabilities4.30M11.26M17.62M11.31M34.83M26.61M72.25M90.35M91.60M80.86M62.85M45.61M40.64M46.69M39.32M51.51M171.50M196.11M214.22M310.95M386.67M426.01M418.05M468.46M462.30M532.70M504.66M
Total Equity51.70M116.70M75.92M77.76M105.25M106.44M31.90M-17.39M-47.06M-23.92M-16.98M-14.71M-20.83M-12.02M-4.48M23.02M70.73M-39.13M-75.82M-174.55M-231.34M-211.50M47.91M-54.90M-148.38M-326.38M-271.11M
Cash46.40M96.14M60.87M33.13M57.21M15.98M33.22M24.22M14.48M24.47M20.07M19.78M10.75M21.47M27.35M40.22M171.67M76.44M60.19M53.05M61.81M99.87M291.93M178.67M76.11M40.44M3.00M
Total Debt3.00M4.98M6.09M550.88K15.87M9.92M4.17M75.48M77.55M67.98M49.64M34.20M32.92M35.92M8.87M6.03M114.47M130.69M163.02M13.36M23.39M55.73M58.29M78.43M350.25M94.87M334.90M
Net Debt-43.40M-91.17M-54.77M-32.58M-41.34M-6.06M-29.05M51.26M63.07M43.51M29.57M14.41M22.18M14.45M-18.49M-34.20M-57.20M54.25M102.84M-39.70M-38.41M-44.14M-233.64M-100.25M274.14M54.43M331.90M

Cash Flow

Currency: USD1999-12-312000-12-312001-12-312002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-13.50M-15.13M-36.83M-50.83M-51.19M-60.22M-66.33M-44.94M-26.69M-28.91M-24.19M-14.76M-16.25M1.01M-19.53M-38.23M-47.18M-79.96M-94.23M-131.09M-18.68M-139.10M10.14M-175.37M-224.20M-158.31M-158.31M
Investing Cash Flow-4.90M-1.63M2.99M-28.17M-32.53M3.93M41.77M15.39M13.19M-4.00M2.16M9.93M-29.46K-103.44K-363.52K-16.81M-31.23M17.60M2.06M-3.59M-4.66M-4.44M-43.15M-33.61M3.40M27.00K27.00K
Financing Cash Flow42.60M66.48M-1.44M51.27M107.80M47.85M41.79M20.55M3.76M42.90M17.63M4.54M7.24M9.81M25.78M52.81M189.58M-2.46M80.54M128.28M31.32M183.85M225.26M95.83M119.87M122.84M122.84M
Capital Expenditure4.90M2.64M1.67M2.31M18.54M3.97M2.66M329.89K11.21K206.01K243.87K130.44K54.55K103.44K813.52K2.82M3.59M12.52M3.12M3.60M4.66M3.47M33.81M53.06M9.95M576.00K576.00K
Free Cash Flow-18.40M-17.78M-38.49M-53.14M-69.72M-64.19M-68.99M-45.27M-26.70M-29.12M-24.44M-14.89M-16.30M909.16K-20.35M-41.05M-50.77M-92.48M-97.35M-134.69M-23.34M-142.56M-23.67M-228.44M-234.16M-158.89M-158.89M
Dividends Paid-----817.01K790.50K790.50K790.50K790.50K790.50K790.50K790.50K592.88K0460.96K01.18M15.99M0--9.13M----
FCF to OCF136.30%117.46%104.52%104.54%136.21%106.59%104.01%100.73%100.04%100.71%101.01%100.88%100.34%89.78%104.16%107.37%107.61%115.66%103.31%102.74%124.93%102.49%-233.31%130.26%104.44%100.36%100.36%
Dividend Paid to FCF------1.27%-1.15%-1.75%-2.96%-2.71%-3.23%-5.31%-4.85%65.21%0.00%-1.12%0.00%-1.28%-16.42%0.00%---38.58%----

Earnings

Report DateApr 24, 2000Jul 25, 2000Oct 26, 2000Feb 21, 2001Apr 24, 2001Jul 24, 2001Oct 23, 2001Feb 20, 2002Apr 23, 2002Jul 25, 2002Oct 23, 2002Feb 19, 2003Apr 16, 2003Jul 23, 2003Oct 23, 2003Feb 19, 2004Apr 20, 2004Jul 22, 2004Oct 19, 2004Feb 24, 2005May 5, 2005Jul 28, 2005Oct 27, 2005Feb 23, 2006May 3, 2006Aug 1, 2006Oct 31, 2006Feb 21, 2007May 8, 2007Aug 2, 2007Nov 1, 2007Feb 21, 2008May 1, 2008Jul 31, 2008Nov 5, 2008Feb 19, 2009May 7, 2009Jul 30, 2009Oct 29, 2009Feb 18, 2010Apr 29, 2010Jul 29, 2010Oct 28, 2010Feb 17, 2011Apr 28, 2011Jul 28, 2011Oct 27, 2011Mar 5, 2012Apr 25, 2012Aug 2, 2012Oct 25, 2012Feb 28, 2013Apr 24, 2013Jul 25, 2013Oct 24, 2013Mar 5, 2014May 8, 2014Jul 24, 2014Oct 31, 2014Feb 26, 2015Apr 23, 2015Jul 23, 2015Oct 27, 2015Mar 3, 2016Apr 28, 2016Jul 28, 2016Oct 27, 2016Mar 9, 2017May 4, 2017Aug 7, 2017Nov 7, 2017Mar 15, 2018May 7, 2018Aug 9, 2018Nov 7, 2018Mar 14, 2019May 10, 2019Aug 9, 2019Nov 4, 2019Mar 12, 2020May 7, 2020Aug 6, 2020Oct 29, 2020Mar 15, 2021May 6, 2021Aug 9, 2021Nov 9, 2021Mar 1, 2022May 10, 2022Aug 9, 2022Nov 8, 2022Mar 14, 2023May 9, 2023Aug 8, 2023Nov 7, 2023Mar 14, 2024May 7, 2024Aug 8, 2024Nov 12, 2024Mar 12, 2025May 12, 2025Aug 11, 2025Nov 10, 2025Mar 16, 2026May 11, 2026Aug 7, 2026Nov 9, 2026
EPS Estimate-1.08-1.11-1.32-1.62-1.62-1.71-1.92-2.34-32.40-34.20-38.40-2.59-52.80-48.00-48.80-2.59-49.60-53.20-121.84-2.40-104.40-49.20-51.10-2.58-116.40-74.64-90.30-1.26-22.80-26.40-27.60-1.38-16.80-21.60-21.60-19.20-14.40--13.20-0.54-7.20-7.20-7.20-0.30-4.80-6.00-5.60-0.28-5.65-5.80-5.60-0.24-4.64-4.40-5.30-0.24-2.40-3.90-2.75-0.16-3.00-2.73-3.27-3.10-0.22-4.60-4.90-0.30-6.60-7.33-6.10-0.29-6.60-7.60-5.20-0.28-6.20-7.60-8.00-7.60-0.33-5.90-5.10-0.22-6.13-4.879.13-0.16-5.80-4.40-3.60-4.33-0.21-3.96-3.95-0.05-3.22-1.33-2.31-2.54-1.981.352.20-1.301.800.050.01
EPS Actual-1.14-1.20-1.14-3.72-1.62-1.86-2.40-2.40-32.40-37.20-183.60-2.94-43.20-50.40-54.00-2.76-49.20-45.60-49.20-2.28-48.00-56.40-45.60-2.34-43.20-37.20-28.80-1.56-22.80-26.40-30.00-0.96-24.00-22.80-20.40-14.4016.80-20.16-15.600.12-12.00-6.00-7.20-0.18-6.00-6.00-5.60-0.295.80-6.20-4.80-0.23-7.00-8.00-4.80-0.160.20-2.42-2.91-0.41-3.40-8.82-4.77-3.83-0.37-4.61-6.84-0.30-3.71-6.40-7.15-0.35-7.51-4.80-5.80-0.402.85-7.60-6.60-4.40-0.31-5.60-5.60-0.20-5.40-7.4013.90-0.26-3.80-3.40-3.80-4.80-0.22-4.00-3.20-0.13-3.04-2.52-3.08-2.04-1.03-1.00-1.160.68-0.03-0.01-
Surprise-5.56%-8.11%13.64%-129.63%0.00%-8.77%-25.00%-2.56%0.00%-8.77%-378.13%-13.51%18.18%-5.00%-10.66%-6.56%0.81%14.29%59.62%5.00%54.02%-14.63%10.76%9.30%62.89%50.16%68.11%-23.81%0.00%0.00%-8.70%30.43%-42.86%-5.56%5.56%25.00%216.67%--18.18%122.22%-66.67%16.67%0.00%40.00%-25.00%0.00%0.00%-3.57%202.65%-6.90%14.29%4.17%-50.86%-81.82%9.43%33.33%108.33%37.95%-5.82%-156.25%-13.33%-223.08%-45.87%-23.55%-68.18%-0.22%-39.59%0.00%43.79%12.69%-17.21%-20.69%-13.79%36.84%-11.54%-42.86%145.97%0.00%17.50%42.11%6.06%5.08%-9.80%9.09%11.91%-51.95%52.25%-62.50%34.48%22.73%-5.56%-10.85%-4.76%-1.01%18.99%-160.00%5.59%-89.47%-33.33%19.75%47.98%-174.07%-152.73%152.37%-101.67%-120.00%-
Timing--------Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-market-Pre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hours-After-hours--

Key Statistics & Ratios

Market Cap385.68M
Enterprise Value401.33M
Trailing P/E2.82
Forward P/E3.73
PEG Ratio1.44
Price / Sales2.91
Price / Book218.61
EPS3.03
Book Value-4.67
Revenue (TTM)132.69M
Gross Profit (TTM)150.75M
EBITDA40.61M
Profit Margin69.34%
Operating Margin32.72%
Return on Equity-1278.83%
Return on Assets12.53%
Shares Outstanding45.16M
Shares Float40.23M
Beta1.40
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 5 analystsTarget 26.33
  • Strong Buy
    1
  • Buy
    1
  • Hold
    3

Ownership Breakdown

Institutions
46.45%
Insiders
6.24%
Retail / Other
47.31%

Top Institutional Holders

  • Vanguard Capital Management, LLC
    1.44M3.20%
  • Vanguard Portfolio Management, LLC
    1.20M2.65%
  • Siren, L.L.C.
    1.06M2.36%
  • Marshall Wace Asset Management Ltd
    688.20K1.53%
  • BlackRock Inc
    545.66K1.21%
  • GlobeFlex Capital, L.P.
    418.58K0.93%
  • Geode Capital Management, LLC
    348.39K0.77%
  • Morgan Stanley - Brokerage Accounts
    295.82K0.66%
  • Renaissance Technologies Corp
    285.65K0.63%
  • Man Group PLC
    278.98K0.62%

Top Fund Holders

  • Vanguard MStar Total Stk Mkt Idx Invest
    1.17M3.31%
  • iShares Russell 2000 ETF
    890.10K2.52%
  • Vanguard Strategic Equity Inv
    511.81K1.45%
  • Fidelity Small Cap Index
    436.49K1.24%
  • iShares Russell 2000 Value ETF
    309.26K0.88%
  • Vanguard Explorer Inv
    290.65K0.82%
  • Vanguard Russell 2000 ETF
    228.64K0.65%
  • Vanguard Strategic Small-Cap Equity Inv
    205.34K0.58%
  • Mackenzie GQE US Small Cap F8
    205.23K0.58%
  • Fidelity Extended Market Index
    202.18K0.57%

Stock Splits

  • Apr 12, 20241:20
  • Oct 3, 20111:6